ReviewFrontiers in immunology2026
HIF-1α-centered metabolic reprogramming in osteoarthritis: cell type-specific effects and intercellular crosstalk among chondrocytes, BMSCs, and macrophages.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a systemic metabolic disorder characterized by cartilage degeneration and pathological changes in the "core functional cell populations" in the joints, i.e., chondrocytes, bone marrow mesenchymal stromal cells (BMSCs), and macrophages. In this review, we summarize the current evidence on HIF-1α-centered metabolic reprogramming in OA, with a focus on its cell type-specific effects in chondrocytes, BMSCs, and macrophages, and discuss how HIF-1α-associated intercellular crosstalk may contribute to cartilage degeneration, synovial inflammation, and impaired endogenous repair. While previous reviews mainly addressed HIF-1α-related hypoxia, glycolysis, mitochondrial dysfunction, inflammation, or therapeutic targeting as separate aspects of OA, this review takes a multicellular perspective to emphasize HIF-1α as a cell type-specific metabolic coordinator that connects chondrocyte degeneration, BMSC dysfunction, macrophage polarization, and metabolite-mediated intercellular communication within the OA microenvironment. These core functional cell populations directly regulate cartilage homeostasis, synovial inflammation, and endogenous repair. It is noted that although osteoblasts and osteoclasts are widely recognized as contributors to OA-related subchondral bone remodeling, they are not classified as core functional cell populations in this review due to their primarily restricted functions to bone metabolism-dominated remodeling within the subchondral bone compartment. Under hypoxic, inflammatory, and oxidative-stress conditions, hypoxia-inducible factor-1α (HIF-1α) regulates glycolysis, mitochondrial function, and inflammatory responses. Therefore, while activation to some extent can aid the response of chondrocytes and BMSCs to hypoxemia and induce tissue repair, over-activation is detrimental, leading to tissue damage and aging of BMSCs, as well as an inflammatory M1-like state in macrophages. Therefore, it is recommended that therapeutic strategies should avoid the general inhibition of HIF-1α but focus on cell-specific regulation and targeted intervention of metabolic nodes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.